Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Adenosine
- Accession Number
- DB00640 (APRD00132)
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Description
A nucleoside that is composed of adenine and d-ribose. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter. [PubChem]
- Structure
Structure for DB00640 (Adenosine)
- Synonyms
- (2R,3R,4S,5R)-2-(6-Aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
- 6-Amino-9-beta-D-ribofuranosyl-9H-purine
- 9-beta-D-Ribofuranosidoadenine
- 9-beta-D-Ribofuranosyl-9H-purin-6-amine
- Ade-rib
- Adenin riboside
- Adenine deoxyribonucleoside
- Adenocor
- Adenosin
- Adenosina
- Adénosine
- Adenosinum
- Adenyldeoxyriboside
- Ado
- beta-D-Adenosine
- Deoxyadenosine
- Desoxyadenosine
- External IDs
- SR 96225 / SR-96225 / USAF CB-10
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Adenocard Solution 3 mg/mL Intravenous Remedy Repack 2015-08-18 2017-09-05 US 
Adenocard Solution 3 mg/mL Intravenous Astellas Pharma Inc 1989-10-30 Not applicable US Adenocard Solution 6 mg/2mL Intravenous Cardinal Health 1989-10-30 Not applicable US Adenocard Solution 3 mg/mL Intravenous Cardinal Health 1989-10-30 Not applicable US Adenocard - Liq Rapid Bolus IV 3mg/ml Solution 3 mg Intravenous Astellas Pharma Inc 1996-08-14 2014-12-05 Canada 
Adenocard Injection -pre-filled Syringe Solution 3 mg Intravenous Astellas Pharma Inc 1994-12-31 Not applicable Canada Adenocard Liq IV 3mg/ml Liquid 3 mg Intravenous Fujisawa Pharmaceutical Co, Division Of Fujisawa Canada Inc. 1993-12-31 1996-09-09 Canada Adenocard Liq IV 3mg/ml (pre-filled Syringe) Liquid 3 mg Intravenous Fujisawa Pharmaceutical Co, Division Of Fujisawa Canada Inc. 1994-12-31 1996-09-09 Canada Adenoscan Solution 3 mg/mL Intravenous Astellas Pharma Inc 1995-05-18 Not applicable US Adenoscan Solution 3 mg/mL Intravenous Remedy Repack 2013-06-10 2016-10-13 US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Adenosine Injection, solution 3 mg/mL Intravenous Remedy Repack 2014-05-23 2016-12-16 US Adenosine Injection, solution 3 mg/mL Intravenous General Injectables & Vaccines 2011-10-05 Not applicable US Adenosine Injection 3 mg/mL Intravenous West Ward Pharmaceutical 2004-06-16 Not applicable US Adenosine Injection 3 mg/mL Intravenous Wockhardt 2009-07-20 Not applicable US Adenosine Injection, solution 3 mg/mL Intravenous Akorn 2014-10-02 Not applicable US Adenosine Injection, solution 3 mg/mL Intravenous AGILA SPECIALTIES PRIVATE LIMITED 2014-03-22 Not applicable US Adenosine Injection, solution 3 mg/mL Intravenous Cardinal Health 2011-03-17 Not applicable US Adenosine Injection, solution 3 mg/mL Intravenous Mylan Institutional 2014-03-28 Not applicable US Adenosine Injection 3 mg/mL Intravenous Sagent Pharmaceuticals 2009-09-01 Not applicable US Adenosine Injection, solution 3 mg/mL Intravenous Teva Parenteral Medicines, Inc. 2013-09-23 Not applicable US - Unapproved/Other Products
Name Dosage Strength Route Labeller Marketing Start Marketing End A.H.C Real Eye For Face Cream .12 mg/30mL Topical Carver Korea Co.,Ltd. 2013-06-21 Not applicable US A.H.C. Collagen Cream Cream 20 mg/50mL Topical Carver Korea Co.,Ltd. 2013-08-15 Not applicable US A.H.C. Collagen Toner Liquid 48 mg/120mL Topical Carver Korea Co.,Ltd. 2013-08-15 Not applicable US Adenosine Injection, solution 3 mg/mL Intravenous Cantrell Drug Company 2015-02-05 Not applicable US Advanced Snail 92 All in One Cream Cream .04 mg/100mL Topical Cosrx Inc. 2016-05-24 2017-06-29 US AHC Collagen Serum Liquid 12 mg/30mL Topical Carver Korea Co.,Ltd. 2013-08-15 Not applicable US AHC Complex Choice EGF Booster Cream .4 mg/mL Topical Carver Korea Co.,Ltd. 2013-08-15 Not applicable US AHC Complex Choice EGF Booster Cream .4 mg/mL Topical Carver Korea Co.,Ltd. 2013-08-15 Not applicable US AHC Hydration Special Gen Cream Cream 20 mg/50mL Topical Carver Korea Co.,Ltd. 2013-07-15 Not applicable US AHC Hydration Special Gen Mask Liquid 12.8 mg/32g Topical Carver Korea Co.,Ltd. 2013-07-15 Not applicable US - International/Other Brands
- Adenocard / Adenocor (Sanofi-Aventis) / Adenoject (Sun) / Adenoscan / Adenoz (Celon) / Adenozer (Purzer) / Adesin (Dae Han New Pharm) / Adrekar (Sanofi-Aventis) / Atépadène (Mayoly-Spindler) / Cardimax (AC Farma) / Cardiovert (Sanofi-Aventis) / Krenosin (Sanofi-Aventis) / Osiden (Square) / Pisdeno (Pisa)
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End A.H.c Cotton 100 Mask Multi Peptide Adenosine (.01 g/25mL) + Allantoin (.025 g/25mL) + Nicotinamide (.05 g/25mL) Patch Topical Carver Korea Co.,Ltd. 2017-09-20 Not applicable US A.H.c Cotton 100 Mask Skin Ceramide Adenosine (.01 g/25mL) + Allantoin (.025 g/25mL) + Nicotinamide (.05 g/25mL) Patch Topical Carver Korea Co.,Ltd. 2017-09-05 Not applicable US A.H.c Cotton 100 Mask Soy Isoflavone Adenosine (.01 g/25mL) + Allantoin (.025 g/25mL) + Nicotinamide (.05 g/25mL) Patch Topical Carver Korea Co.,Ltd. 2017-09-14 Not applicable US A.H.c Cotton 100 Mask Triple Hyaluronic Adenosine (.01 g/25mL) + Allantoin (.025 g/25mL) + Nicotinamide (.05 g/25mL) Patch Topical Carver Korea Co.,Ltd. 2017-09-20 Not applicable US Abalone Aqua Flood Water Adenosine (.04 g/100mL) + Nicotinamide (2 g/100mL) Cream Topical C&bcosmetic Co.,ltd. 2017-02-16 Not applicable US ABALONE CrystalDouble EX Adenosine (.04 g/100mL) + Nicotinamide (2 g/100mL) Cream Topical C&bcosmetic Co.,ltd. 2017-02-16 Not applicable US Abalone Crystaldouble EX Ampoule Adenosine (.044 g/100mL) + Arbutin (2.2 g/100mL) Liquid Topical C&bcosmetic Co.,ltd. 2017-03-10 Not applicable US Abalone Crystaldouble EX Bb Adenosine (.04 g/100mL) + Nicotinamide (2 g/100mL) + Octinoxate (2 g/100mL) + Octocrylene (3 g/100mL) + Titanium dioxide (9.9 g/100mL) Cream Topical C&bcosmetic Co.,ltd. 2017-03-10 Not applicable US Abalone Crystaldouble EX Cc Adenosine (.04 g/100mL) + Nicotinamide (2 g/100mL) + Octinoxate (7 g/100mL) + Titanium dioxide (4.694 g/100mL) Cream Topical C&bcosmetic Co.,ltd. 2017-03-10 Not applicable US Abalone Crystaldouble EX Homme Adenosine (.04 g/100mL) + Nicotinamide (2 g/100mL) Cream Topical C&bcosmetic Co.,ltd. 2017-02-20 Not applicable US - Categories
- Adenosine
- Alkenes
- Analgesics
- Anti-Arrhythmia Agents
- Biological Factors
- Carbohydrates
- Cardiac Therapy
- Cardiovascular Agents
- Cardiovascular System
- Central Nervous System Agents
- Cyclohexanes
- Cyclohexenes
- Cycloparaffins
- Deoxyribonucleosides
- Enzymes
- Enzymes and Coenzymes
- Glycosides
- Hydrocarbons, Acyclic
- Mutagens
- Neurotransmitter Agents
- Noxae
- Nucleic Acids, Nucleotides, and Nucleosides
- Nucleosides
- Oxidoreductases
- Peripheral Nervous System Agents
- Pigments, Biological
- Polyenes
- Purine Nucleosides
- Purinergic Agents
- Purinergic Agonists
- Purinergic P1 Receptor Agonists
- Purines
- Ribonucleosides
- Sensory System Agents
- Terpenes
- Toxic Actions
- Vasodilator Agents
- UNII
- K72T3FS567
- CAS number
- 58-61-7
- Weight
- Average: 267.2413
Monoisotopic: 267.096753929 - Chemical Formula
- C10H13N5O4
- InChI Key
- OIRDTQYFTABQOQ-KQYNXXCUSA-N
- InChI
- InChI=1S/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)/t4-,6-,7-,10-/m1/s1
- IUPAC Name
- (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
- SMILES
- NC1=C2N=CN([[email protected]@H]3O[[email protected]](CO)[[email protected]@H](O)[[email protected]]3O)C2=NC=N1
Pharmacology
- Indication
Used as an initial treatment for the termination of paroxysmal supraventricular tachycardia (PVST), including that associated with accessory bypass tracts, and is a drug of choice for terminating stable, narrow-complex supraventricular tachycardias (SVT). Also used as an adjunct to thallous chloride TI 201 myocardial perfusion scintigraphy (thallium stress test) in patients who are unable to exercise adequately, as well as an adjunct to vagal maneuvers and clinical assessment to establish a specific diagnosis of undefined, stable, narrow-complex SVT.
- Structured Indications
- Pharmacodynamics
Adenosine is an endogenous nucleoside occurring in all cells of the body and is not chemically related to other antiarrhythmic drugs. Adenosine may exert its pharmacologic effects by activation of purine (cell surface A1 and A2 adenosine) receptors, as well as relax vascular smooth muscles through the reduction in calcium uptake by inhibition of slow inward calcium current and activation of adenylate cyclase in smooth muscle cells. Adenosine may reduce vascular tone by modulation of sympathetic neurotransmission. The drug also has negative chronotropic, dromotropic, and inotropic effects on the heart by slowing conduction time throught he AV node and interrupting AV nodal reentry pathways. Adenosine is a potent vasodilator in most vascular beds, but vasoconstriction is produced in renal afferent arterioles and hepatic veins. The drug produces a net mild to moderate reduction in systolic, diastolic, and mean arterial blood pressure and a reflex increase in heart rate. Adenosine is antagonized competitively by methylxanthines such as caffeine and theophylline, and potentiated by blockers of nucleoside transport such as dipyridamole. Adenosine is not blocked by atropine.
- Mechanism of action
Adenosine slows conduction time through the AV node and can interrupt the reentry pathways through the AV node, resulting in the restoration of normal sinus rhythm in patients with paroxysmal supraventricular tachycardia (PSVT), including PSVT associated with Wolff-Parkinson-White Syndrome. This effect may be mediated through the drug's activation of cell-surface A1 and A2 adenosine receptors. Adenosine also inhibits the slow inward calcium current and activation of adenylate cyclase in smooth muscle cells, thereby causing relaxation of vascular smooth muscle. By increasing blood flow in normal coronary arteries with little or no increase in stenotic arteries (with little to no increase in stenotic arteries), adenosine produces a relative difference in thallous (thallium) chloride TI 201 uptake in myocardium supplied by normal verus stenotic coronary arteries.
Target Actions Organism AAdenosine receptor A2a agonistHuman AAdenosine receptor A2b agonistHuman AAdenosine receptor A3 agonistHuman AAdenosine receptor A1 agonistHuman - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
Intracellular adenosine is rapidly metabolized either via phosphorylation to adenosine monophosphate by adenosine kinase, or via deamination to inosine by adenosine deaminase in the cytosol.
- Route of elimination
- Not Available
- Half life
Less than 10 secs
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group Ambroxol acefyllinate The therapeutic efficacy of Adenosine can be decreased when used in combination with Ambroxol acefyllinate. Experimental Aminophylline The therapeutic efficacy of Adenosine can be decreased when used in combination with Aminophylline. Approved Caffeine The therapeutic efficacy of Adenosine can be decreased when used in combination with Caffeine. Approved Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Adenosine. Approved, Investigational Digoxin The risk or severity of adverse effects can be increased when Digoxin is combined with Adenosine. Approved Dipyridamole The risk or severity of adverse effects can be increased when Dipyridamole is combined with Adenosine. Approved Dyphylline The therapeutic efficacy of Adenosine can be decreased when used in combination with Dyphylline. Approved Nicotine Nicotine may increase the atrioventricular blocking (AV block) activities of Adenosine. Approved Theophylline The therapeutic efficacy of Adenosine can be decreased when used in combination with Theophylline. Approved - Food Interactions
- Avoid caffeine containing foods and drinks.
References
- Synthesis Reference
Giorgio Stramentinoli, Federico Gennari, "Process for preparing adenosine derivatives of anti-inflammatory and analgesic activity." U.S. Patent US4373097, issued October, 1965.
US4373097- General References
- Not Available
- External Links
- ATC Codes
- C01EB10 — Adenosine
- AHFS Codes
- 24:04.04.24 — Class IV Antiarrythmics
- 24:04.92 — Miscellaneous Cardiac Drugs
- 92:00.00 — Miscellaneous Therapeutic Agents
- PDB Entries
- 1bx4 / 1d4f / 1dgm / 1fmo / 1ho5 / 1jdv / 1jg2 / 1jg3 / 1lii / 1lik … show 138 more
- FDA label
- Download (154 KB)
- MSDS
- Download (72.7 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Astellas pharma us inc
- Akorn inc
- App pharmaceuticals llc
- Baxter healthcare corp
- Bedford laboratories div ben venue laboratories inc
- Gland pharma ltd
- Luitpold pharmaceuticals inc
- Strides arcolab ltd
- Teva parenteral medicines inc
- Wockhardt ltd
- Packagers
- APP Pharmaceuticals
- A-S Medication Solutions LLC
- Astellas Pharma Inc.
- Baxter International Inc.
- Bedford Labs
- Ben Venue Laboratories Inc.
- General Injectables and Vaccines Inc.
- Gland Pharma Ltd.
- Hospira Inc.
- Physicians Total Care Inc.
- Sagent Pharmaceuticals
- Spectrum Pharmaceuticals
- Strides Arcolab Limited
- Teva Pharmaceutical Industries Ltd.
- Wockhardt Ltd.
- Dosage forms
Form Route Strength Cream Topical .12 mg/30mL Liquid Topical 48 mg/120mL Solution Intravenous 6 mg/2mL Liquid Intravenous 3 mg Solution Intravenous 3 mg/mL Injection Intravenous 3 mg/mL Injection, solution Intravenous 3 mg/mL Cream Topical .04 mg/100mL Cream Topical .4 mg/mL Cream Topical 20 mg/50mL Liquid Topical 12.8 mg/32g Liquid Topical 12 mg/30mL Liquid Topical 54 mg/135mL Liquid Topical Liquid Topical 12 mg/30g Solution Topical .002 g/6mL Solution Topical 2.8 mg/7mL Liquid Topical .012 g/30mL Gel Topical Cream Topical .04 g/100mL Liquid Topical .05 g/130mL Cream Topical .01 g/45mL Cream Topical .02 g/50mL Cream Topical .01 g/30mL Solution Topical 1.2 mg/3mL Patch Topical .008 g/20g Liquid Topical .6 mg/6mL Cream Topical .04 mL/100mL Cream Topical .004 g/10g Gel Topical .04 g/100g Cream Topical .03 g/95g Liquid Topical 20 mg/50mL Gel Topical .04 g/100mL Cream Topical .04 g/100g Liquid Topical 6 mg/15mL Liquid Topical .04 g/100mL Emulsion Topical .04 g/100g Solution / drops Topical Cream Topical Liquid Topical .04 g/100g Kit Topical Cream Topical .0428 g/100g Kit Topical Cream Topical .2 g/100g Liquid Topical 2 mg/5mL Patch Topical .01 g/25g Liquid Topical 25 mg/50mL Liquid Topical .02 g/50mL Cream Topical .0004 mL/mL Liquid Topical .0004 mL/mL Cream Topical .0004 g/g Emulsion Topical .04 g/100mL Kit Lotion Topical Patch Topical .5 g/25g Cream Topical 6 g/150g Cream Topical .004 mg/10g Cream Topical .08 mg/20mL Patch Topical .6 mg/3g Cream Topical .02 mg/50mL Liquid Topical .05 mg/125mL Patch Topical .014 g/35g Cream Topical .01 g/27g Liquid Topical .04 mg/100mL Lipstick Topical .001 g/3.5g Patch Topical Liquid Topical .00012 mg/.3mL Cream Topical .00012 mg/.3mL Cream Topical .011 mg/27mL Cream Topical .001 mg/2.5mL Oil Topical .01 g/30mL Solution Intravenous 3 mg Cream Topical .0004 1/100mL Oil Topical Solution Topical Cream Topical .01 g/25g Patch Topical 1 g/100g Spray Topical Cream Topical .018 g/45mL Cream Topical .012 g/30mL Cream Topical .4 mg/g Cream Topical .002 g/10g Cream Topical .04 mL/mL Lotion Topical .05 g/100mL Cream Topical .05 g/100mL Patch Topical .01 g/25mL Liquid Topical .001 g/3mL Patch Topical .009 g/24mL Patch Topical .008 g/20mL Liquid Topical .001 g/4mL Lotion Topical 1 mg/150mL Liquid Topical .04 mL/100mL Cream Topical .02 g/50g Cream Topical .024 g/60g Powder Topical Emulsion Topical Emulsion Topical .06 g/150mL Liquid Topical .06 g/150mL - Prices
Unit description Cost Unit Adenosine-5 monophosphate 19.74USD g Adenosine powder 15.86USD g Adenoscan 3 mg/ml vial 10.09USD ml Adenosine 12 mg/4 ml vial 8.44USD ml Adenosine 6 mg/2 ml vial 8.1USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US5731296 No 1995-03-24 2015-03-24 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 235.5 °C PhysProp water solubility 8230 mg/L Not Available logP -1.05 HANSCH,C ET AL. (1995) - Predicted Properties
Property Value Source Water Solubility 14.0 mg/mL ALOGPS logP -1.2 ALOGPS logP -2.1 ChemAxon logS -1.3 ALOGPS pKa (Strongest Acidic) 12.45 ChemAxon pKa (Strongest Basic) 4.99 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 8 ChemAxon Hydrogen Donor Count 4 ChemAxon Polar Surface Area 139.54 Å2 ChemAxon Rotatable Bond Count 2 ChemAxon Refractivity 63.2 m3·mol-1 ChemAxon Polarizability 25.27 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9227 Blood Brain Barrier + 0.9383 Caco-2 permeable - 0.8957 P-glycoprotein substrate Non-substrate 0.7026 P-glycoprotein inhibitor I Non-inhibitor 0.966 P-glycoprotein inhibitor II Non-inhibitor 0.9533 Renal organic cation transporter Non-inhibitor 0.9444 CYP450 2C9 substrate Non-substrate 0.8639 CYP450 2D6 substrate Non-substrate 0.8349 CYP450 3A4 substrate Non-substrate 0.5866 CYP450 1A2 substrate Non-inhibitor 0.9667 CYP450 2C9 inhibitor Non-inhibitor 0.9595 CYP450 2D6 inhibitor Non-inhibitor 0.977 CYP450 2C19 inhibitor Non-inhibitor 0.9514 CYP450 3A4 inhibitor Non-inhibitor 0.962 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9701 Ames test Non AMES toxic 0.9133 Carcinogenicity Non-carcinogens 0.9182 Biodegradation Not ready biodegradable 0.9738 Rat acute toxicity 1.9715 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.989 hERG inhibition (predictor II) Non-inhibitor 0.9102
Spectra
- Mass Spec (NIST)
- Download (9.12 KB)
- Spectra
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as purine nucleosides. These are compounds comprising a purine base attached to a ribosyl or deoxyribosyl moiety.
- Kingdom
- Organic compounds
- Super Class
- Nucleosides, nucleotides, and analogues
- Class
- Purine nucleosides
- Sub Class
- Not Available
- Direct Parent
- Purine nucleosides
- Alternative Parents
- Glycosylamines / Pentoses / 6-aminopurines / Aminopyrimidines and derivatives / N-substituted imidazoles / Imidolactams / Tetrahydrofurans / Heteroaromatic compounds / Secondary alcohols / Oxacyclic compounds show 5 more
- Substituents
- Purine nucleoside / Glycosyl compound / N-glycosyl compound / 6-aminopurine / Pentose monosaccharide / Imidazopyrimidine / Purine / Aminopyrimidine / Monosaccharide / N-substituted imidazole show 21 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- adenosines (CHEBI:16335) / Ribonucleosides (C00212)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Identical protein binding
- Specific Function
- Receptor for adenosine. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.
- Gene Name
- ADORA2A
- Uniprot ID
- P29274
- Uniprot Name
- Adenosine receptor A2a
- Molecular Weight
- 44706.925 Da
References
- Trincavelli ML, Daniele S, Martini C: Adenosine receptors: what we know and what we are learning. Curr Top Med Chem. 2010;10(9):860-77. [PubMed:20370662]
- Schenone S, Brullo C, Musumeci F, Bruno O, Botta M: A1 receptors ligands: past, present and future trends. Curr Top Med Chem. 2010;10(9):878-901. [PubMed:20370661]
- Ezeamuzie CI, Khan I: The role of adenosine A(2) receptors in the regulation of TNF-alpha production and PGE(2) release in mouse peritoneal macrophages. Int Immunopharmacol. 2007 Apr;7(4):483-90. Epub 2006 Dec 29. [PubMed:17321471]
- Kreckler LM, Wan TC, Ge ZD, Auchampach JA: Adenosine inhibits tumor necrosis factor-alpha release from mouse peritoneal macrophages via A2A and A2B but not the A3 adenosine receptor. J Pharmacol Exp Ther. 2006 Apr;317(1):172-80. Epub 2005 Dec 9. [PubMed:16339914]
- Kreckler LM, Gizewski E, Wan TC, Auchampach JA: Adenosine suppresses lipopolysaccharide-induced tumor necrosis factor-alpha production by murine macrophages through a protein kinase A- and exchange protein activated by cAMP-independent signaling pathway. J Pharmacol Exp Ther. 2009 Dec;331(3):1051-61. doi: 10.1124/jpet.109.157651. Epub 2009 Sep 11. [PubMed:19749080]
- Buenestado A, Grassin Delyle S, Arnould I, Besnard F, Naline E, Blouquit-Laye S, Chapelier A, Bellamy JF, Devillier P: The role of adenosine receptors in regulating production of tumour necrosis factor-alpha and chemokines by human lung macrophages. Br J Pharmacol. 2010 Mar;159(6):1304-11. doi: 10.1111/j.1476-5381.2009.00614.x. Epub 2010 Feb 5. [PubMed:20136829]
- Funakoshi H, Zacharia LC, Tang Z, Zhang J, Lee LL, Good JC, Herrmann DE, Higuchi Y, Koch WJ, Jackson EK, Chan TO, Feldman AM: A1 adenosine receptor upregulation accompanies decreasing myocardial adenosine levels in mice with left ventricular dysfunction. Circulation. 2007 May 1;115(17):2307-15. Epub 2007 Apr 16. [PubMed:17438146]
- Haschemi A, Wagner O, Marculescu R, Wegiel B, Robson SC, Gagliani N, Gallo D, Chen JF, Bach FH, Otterbein LE: Cross-regulation of carbon monoxide and the adenosine A2a receptor in macrophages. J Immunol. 2007 May 1;178(9):5921-9. [PubMed:17442976]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- G-protein coupled adenosine receptor activity
- Specific Function
- Receptor for adenosine. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.
- Gene Name
- ADORA2B
- Uniprot ID
- P29275
- Uniprot Name
- Adenosine receptor A2b
- Molecular Weight
- 36332.655 Da
References
- Trincavelli ML, Daniele S, Martini C: Adenosine receptors: what we know and what we are learning. Curr Top Med Chem. 2010;10(9):860-77. [PubMed:20370662]
- Schenone S, Brullo C, Musumeci F, Bruno O, Botta M: A1 receptors ligands: past, present and future trends. Curr Top Med Chem. 2010;10(9):878-901. [PubMed:20370661]
- Ezeamuzie CI, Khan I: The role of adenosine A(2) receptors in the regulation of TNF-alpha production and PGE(2) release in mouse peritoneal macrophages. Int Immunopharmacol. 2007 Apr;7(4):483-90. Epub 2006 Dec 29. [PubMed:17321471]
- Kreckler LM, Wan TC, Ge ZD, Auchampach JA: Adenosine inhibits tumor necrosis factor-alpha release from mouse peritoneal macrophages via A2A and A2B but not the A3 adenosine receptor. J Pharmacol Exp Ther. 2006 Apr;317(1):172-80. Epub 2005 Dec 9. [PubMed:16339914]
- Buenestado A, Grassin Delyle S, Arnould I, Besnard F, Naline E, Blouquit-Laye S, Chapelier A, Bellamy JF, Devillier P: The role of adenosine receptors in regulating production of tumour necrosis factor-alpha and chemokines by human lung macrophages. Br J Pharmacol. 2010 Mar;159(6):1304-11. doi: 10.1111/j.1476-5381.2009.00614.x. Epub 2010 Feb 5. [PubMed:20136829]
- Funakoshi H, Zacharia LC, Tang Z, Zhang J, Lee LL, Good JC, Herrmann DE, Higuchi Y, Koch WJ, Jackson EK, Chan TO, Feldman AM: A1 adenosine receptor upregulation accompanies decreasing myocardial adenosine levels in mice with left ventricular dysfunction. Circulation. 2007 May 1;115(17):2307-15. Epub 2007 Apr 16. [PubMed:17438146]
- Haschemi A, Wagner O, Marculescu R, Wegiel B, Robson SC, Gagliani N, Gallo D, Chen JF, Bach FH, Otterbein LE: Cross-regulation of carbon monoxide and the adenosine A2a receptor in macrophages. J Immunol. 2007 May 1;178(9):5921-9. [PubMed:17442976]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- G-protein coupled adenosine receptor activity
- Specific Function
- Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibits adenylyl cyclase. Possible role in reproduction.
- Gene Name
- ADORA3
- Uniprot ID
- P0DMS8
- Uniprot Name
- Adenosine receptor A3
- Molecular Weight
- 36184.175 Da
References
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Trincavelli ML, Daniele S, Martini C: Adenosine receptors: what we know and what we are learning. Curr Top Med Chem. 2010;10(9):860-77. [PubMed:20370662]
- Schenone S, Brullo C, Musumeci F, Bruno O, Botta M: A1 receptors ligands: past, present and future trends. Curr Top Med Chem. 2010;10(9):878-901. [PubMed:20370661]
- Ezeamuzie CI, Khan I: The role of adenosine A(2) receptors in the regulation of TNF-alpha production and PGE(2) release in mouse peritoneal macrophages. Int Immunopharmacol. 2007 Apr;7(4):483-90. Epub 2006 Dec 29. [PubMed:17321471]
- Kreckler LM, Wan TC, Ge ZD, Auchampach JA: Adenosine inhibits tumor necrosis factor-alpha release from mouse peritoneal macrophages via A2A and A2B but not the A3 adenosine receptor. J Pharmacol Exp Ther. 2006 Apr;317(1):172-80. Epub 2005 Dec 9. [PubMed:16339914]
- Buenestado A, Grassin Delyle S, Arnould I, Besnard F, Naline E, Blouquit-Laye S, Chapelier A, Bellamy JF, Devillier P: The role of adenosine receptors in regulating production of tumour necrosis factor-alpha and chemokines by human lung macrophages. Br J Pharmacol. 2010 Mar;159(6):1304-11. doi: 10.1111/j.1476-5381.2009.00614.x. Epub 2010 Feb 5. [PubMed:20136829]
- Funakoshi H, Zacharia LC, Tang Z, Zhang J, Lee LL, Good JC, Herrmann DE, Higuchi Y, Koch WJ, Jackson EK, Chan TO, Feldman AM: A1 adenosine receptor upregulation accompanies decreasing myocardial adenosine levels in mice with left ventricular dysfunction. Circulation. 2007 May 1;115(17):2307-15. Epub 2007 Apr 16. [PubMed:17438146]
- Haschemi A, Wagner O, Marculescu R, Wegiel B, Robson SC, Gagliani N, Gallo D, Chen JF, Bach FH, Otterbein LE: Cross-regulation of carbon monoxide and the adenosine A2a receptor in macrophages. J Immunol. 2007 May 1;178(9):5921-9. [PubMed:17442976]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Purine nucleoside binding
- Specific Function
- Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase.
- Gene Name
- ADORA1
- Uniprot ID
- P30542
- Uniprot Name
- Adenosine receptor A1
- Molecular Weight
- 36511.325 Da
References
- Trincavelli ML, Daniele S, Martini C: Adenosine receptors: what we know and what we are learning. Curr Top Med Chem. 2010;10(9):860-77. [PubMed:20370662]
- Schenone S, Brullo C, Musumeci F, Bruno O, Botta M: A1 receptors ligands: past, present and future trends. Curr Top Med Chem. 2010;10(9):878-901. [PubMed:20370661]
- Ezeamuzie CI, Khan I: The role of adenosine A(2) receptors in the regulation of TNF-alpha production and PGE(2) release in mouse peritoneal macrophages. Int Immunopharmacol. 2007 Apr;7(4):483-90. Epub 2006 Dec 29. [PubMed:17321471]
- Buenestado A, Grassin Delyle S, Arnould I, Besnard F, Naline E, Blouquit-Laye S, Chapelier A, Bellamy JF, Devillier P: The role of adenosine receptors in regulating production of tumour necrosis factor-alpha and chemokines by human lung macrophages. Br J Pharmacol. 2010 Mar;159(6):1304-11. doi: 10.1111/j.1476-5381.2009.00614.x. Epub 2010 Feb 5. [PubMed:20136829]
- Funakoshi H, Zacharia LC, Tang Z, Zhang J, Lee LL, Good JC, Herrmann DE, Higuchi Y, Koch WJ, Jackson EK, Chan TO, Feldman AM: A1 adenosine receptor upregulation accompanies decreasing myocardial adenosine levels in mice with left ventricular dysfunction. Circulation. 2007 May 1;115(17):2307-15. Epub 2007 Apr 16. [PubMed:17438146]
- Haschemi A, Wagner O, Marculescu R, Wegiel B, Robson SC, Gagliani N, Gallo D, Chen JF, Bach FH, Otterbein LE: Cross-regulation of carbon monoxide and the adenosine A2a receptor in macrophages. J Immunol. 2007 May 1;178(9):5921-9. [PubMed:17442976]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Zinc ion binding
- Specific Function
- Catalyzes the hydrolytic deamination of adenosine and 2-deoxyadenosine. Plays an important role in purine metabolism and in adenosine homeostasis. Modulates signaling by extracellular adenosine, an...
- Gene Name
- ADA
- Uniprot ID
- P00813
- Uniprot Name
- Adenosine deaminase
- Molecular Weight
- 40764.13 Da
References
- Kopff M, Kopff A, Puczkowski S: [Adenosine deaminase: isoenzymes ADA1 and ADA2]. Pol Merkur Lekarski. 1997 Dec;3(18):288-90. [PubMed:9523470]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Poly(a) rna binding
- Specific Function
- ATP dependent phosphorylation of adenosine and other related nucleoside analogs to monophosphate derivatives. Serves as a potential regulator of concentrations of extracellular adenosine and intrac...
- Gene Name
- ADK
- Uniprot ID
- P55263
- Uniprot Name
- Adenosine kinase
- Molecular Weight
- 40545.075 Da
References
- Boison D: Adenosine kinase, epilepsy and stroke: mechanisms and therapies. Trends Pharmacol Sci. 2006 Dec;27(12):652-8. Epub 2006 Oct 23. [PubMed:17056128]
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Pyrimidine- and adenine-specific:sodium symporter activity
- Specific Function
- Sodium-dependent, pyrimidine- and purine-selective. Involved in the homeostasis of endogenous nucleosides. Exhibits the transport characteristics of the nucleoside transport system cib or N3 subtyp...
- Gene Name
- SLC28A3
- Uniprot ID
- Q9HAS3
- Uniprot Name
- Solute carrier family 28 member 3
- Molecular Weight
- 76929.61 Da
References
- Badagnani I, Chan W, Castro RA, Brett CM, Huang CC, Stryke D, Kawamoto M, Johns SJ, Ferrin TE, Carlson EJ, Burchard EG, Giacomini KM: Functional analysis of genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3). Pharmacogenomics J. 2005;5(3):157-65. [PubMed:15738947]
Drug created on June 13, 2005 07:24 / Updated on October 21, 2017 19:24